Dr. Philip M. Arlen to give scientific presentation at two conferences
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody. READ FULL ARTICLE
Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...
Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...